SF3B1 and myelodysplastic syndrome: Most recently, the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) provided supporting evidence that shows the recognition of SF3B1-mutant MDS as a distinct diagnostic entity [34].